PPX™ is the patient's own platelet-derived extracellular vesicles — collected chair-side, concentrated in an FDA-registered laboratory, and documented with a per-prep certificate of analysis. The body's own messengers, brought to specification.
Extracellular vesicles are the body's natural cell-to-cell signaling system, carrying proteins and microRNA between cells. PPX™ isolates these vesicles from the patient's own platelets, then concentrates and documents the recovered fraction.
PPX™ ships you a complete processing kit — needles, tubes, return packaging. The draw happens in your chair. The concentration happens in an FDA-registered lab. The prep ships back ready to inject.
Each tier delivers documented extracellular vesicle counts — verified by nanoparticle tracking analysis on every prep.
Autologous biologics live or die on documentation. PPX™ standardizes the manufacturing and documents every prep. Every time.
PPX™ starts with the patient's own platelets — drawn chair-side. Fully autologous means no donor concerns, no allogenic regulatory questions, no compatibility issues.
Multi-step centrifugation removes red cells, leukocytes, and plasma debris. What's left is the concentrated platelet-derived EV fraction — the cargo that carries growth factors and microRNA.
Every preparation ships with a certificate of analysis documenting sterility, identity, and nanoparticle count — confirming exactly what's in the vial before it reaches the patient.
A standard chair-side blood draw is sealed and shipped overnight to an FDA-registered, cGMP-compliant lab. Multi-step centrifugation isolates the EV fraction. Final product ships back in two 1mL vials, ready to inject.
Per Florida Senate Bill 1768 (effective July 1, 2025), stem cell therapies as defined in the statute are available to FL physicians for the following therapeutic indications.
Autologous biologics live or die on documentation. Here's the paper trail that comes standard with every PPX™ prep.
Patient's Own · Concentrated · Documented
Drop your details and we'll be in touch within 24 hours to coordinate a demo, kit pricing, or a quick strategy call for your practice.
Florida Senate Bill 1768 became law on July 1, 2025 and amended FS §458.3245 and FS §459.0127, making stem cell therapies as defined in the statute available for the following therapeutic indications: orthopedics, wound care, and pain management. Material on this page is intended for general informational and educational purposes only and is not intended to provide medical advice, diagnosis, or treatment recommendations. ZEO ScientifiX does not make any medical claims regarding any of these products. Patient Pure X™ (PPX™) is an autologous preparation manufactured from the patient's own blood. Content may reference investigational biologics or devices not approved by the FDA. This material is intended for Florida physicians only. Any mention of product usage is for therapeutic use only in the states of Florida and Utah. Subject to change without notice. Revive Aesthetics is an authorized distribution partner.